NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-288-2016-0-US-04 Biomarkers And Vaccine Candidates For Filarial Parasites US DIV 17/076,616 Pending
NCI E-185-2019-0-CN-05 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors CN National Stage 202080074414.2 Pending
NCI E-185-2019-0-EP-06 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors EP National Stage 20804404.0 Pending
NCI E-185-2019-0-JP-07 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors JP National Stage 2022-523456 Pending
NIAID E-018-2018-0-AU-04 CHIMERIC VECTORS AU National Stage 2019261570 Pending
NCI E-185-2019-0-AU-03 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors AU National Stage 2020370125 Pending
NCI E-185-2019-0-CA-04 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors CA National Stage 3156761 Pending
NIMH E-259-2016-0-US-05 RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF US DIV 17/074,832 Abandoned
NCI E-094-2018-0-CA-04 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF CA National Stage 3097858 Pending
NIAID E-018-2018-0-CA-06 CHIMERIC VECTORS CA National Stage 3097888 Pending
NCI E-028-2015-1-SA-37 T CELL RECEPTORS SPECIFIC FOR MUTATED KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG SA DIV 520420365 Issued
NHGRI E-175-2019-0-PCT-02 SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA PCT PCT PCT/US2020/55836 Expired
NCI E-097-2018-0-EP-08 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES EP National Stage 19714007.2 Pending
NCI E-040-2012-0-IL-58 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen IL DIV 278003 Pending
NCI E-097-2018-0-KR-11 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES KR National Stage 2020-7029302 Pending
NCI E-105-2012-0-EP-27 Murine Anti-NY-ESO-1 T Cell Receptors EP DIV 20201340.5 Pending
NCI E-174-2019-0-PCT-02 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PCT PCT PCT/US2020/055077 Expired
NCI E-174-2019-0-CN-03 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA CN National Stage 202080071446.7 Pending
NHLBI E-219-2018-2-US-03 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging US National Stage 17/046,193 Pending
NCI E-100-2018-0-EP-03 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF
TYPE II NKT CELLS AND USES THEREOF 		EP National Stage 19 716 658.0 Pending
NCI E-230-2012-0-KR-62 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 KR DIV 10-2020-7028713 Issued
NIAID E-185-2015-0-US-06 EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE US DIV 17/064,496 Pending
NEI E-050-2015-0-JP-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa JP DIV 2020-167984 Pending
NHLBI E-078-2019-0-US-03 HELICAL GUIDEWIRES AND RELATED SYSTEMS US ORD 17/038,095 Pending
NHGRI E-217-2018-0-PCT-02 NOVEL VECTORS AND USES THEREOF PCT PCT PCT/US2020/053353
NCI E-105-2018-0-US-06 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data US National Stage 17/042,765 Pending
NCI E-085-2013-0-HK-27 CD8+ T CELLS THAT ALSO EXPRESS PD-1 AND/OR TIM-3 FOR THE
TREATMENT OF CANCER 		HK EP 42020016957.1 Pending
NCI E-230-2012-0-HK-61 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 HK EP 42020016865.6 Issued
NHGRI E-185-2014-0-US-12 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER US DIV 17/033,166 Pending
NHLBI E-076-2021-0-US-03 Systems And Methods For Applying Pressure To A Bodily Organ US ORD 17/032,283 Pending
NCI E-100-2018-0-US-04 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF US National Stage 17/041,604 Pending
NHLBI E-076-2021-0-PCT-02 Systems And Methods For Applying Pressure To A Bodily Organ PCT PCT PCT/US2020/052690 Expired
NCI E-097-2018-0-EA-07 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES EA National Stage 202092044 Pending
NCI E-176-2014-0-MX-56 Anti-Human Papillomavirus 16 E7 T Cell Receptors MX DIV MX/a/2020/010035 Pending
NCI E-042-2014-0-EP-06 Chimeric Antigen Receptors Targeting CD-19 EP National Stage 20197459.9 Issued
NCI E-113-2018-0-US-08 COMBINATION OF NEAR INFRARED PHTOIMMUNOTHERAPY TARGETING CANCER CELLS AND HOST-IMMUNE ACTIVATION US National Stage 17/040,426 Pending
NIAID E-052-2017-4-EP-50 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection EP DIV 20197556.2 Pending
NCI E-042-2014-0-EP-25 Chimeric Antigen Receptors Targeting CD-19 EP DIV 20197459.9 Pending
NIMH E-345-2013-0-US-08 Monitoring The Effects Of Sleep Deprivation Using Neuronal Avalanches US CON 17/028,901 Abandoned
NCI E-209-2014-0-US-18 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO US CON 17/026,724 11781955 Issued PDF
NIDA E-017-2018-0-US-04 Novel Biased Potent Opioid-like Agonists As Improved Medications To Treat Chronic And Acute Pain US National Stage 16/982,196 11352365 Issued PDF
NCI E-168-2018-0-PCT-02 METHODS OF ISOLATING T CELL POPULATIONS PCT PCT PCT/US2020/051548 Expired
NCI E-168-2018-0-EP-04 METHODS OF ISOLATING T CELL POPULATIONS EP National Stage 20786149.3 Pending
NHGRI E-044-2013-1-US-18 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA US CON 17/024,100 11802283 Issued PDF
NCI E-176-2022-0-PC-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease PCT PCT PCT/EP2020/075948 Expired
NCI E-176-2022-0-US-02 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease US National Stage 17/753,706 Pending
NCI E-176-2022-0-EP-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease EP National Stage 20774960.7 Pending
NCI E-176-2022-0-HK-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease HK EP 62023066863.9 Pending
NCI E-176-2022-0-KR-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease KR National Stage 10-2022-7008878 Pending
NCI E-176-2022-0-IL-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease IL National Stage 1991-09-29 Pending